Abstract 4891
Background
Stereotactic body radiation therapy (SBRT) has been shown to have high efficacy to early-stage hepatocellular carcinoma (HCC) and is expected as an alternative to radiofrequency ablation (RFA). However, how liver function is impaired by SBRT, an important factor in the therapy for HCC, is uncertain. In this study, we compared the impact of SBRT on liver function and that of RFA.
Methods
We retrospectively analyzed 140 patients with single small (≤3 cm) hepatocellular carcinoma treated with SBRT or RFA between January 2014 and January 2019 in Kurashiki Central Hospital. A median age was 75 years, and 101 patients were male. Liver function was assessed by the albumin-bilirubin (ALBI) score before treatment (pre-ALBI) and 3 months after treatment (post-ALBI). Patients in the SBRT group were matched at a 1:1 ratio with patients treated with RFA by using propensity score method, and post-ALBI scores were compared between the two groups.
Results
Among the 140 patients, 42 and 98 patients were treated with SBRT and RFA, respectively. Before matching, patients in SBRT group were significantly older than patients in RFA group (78 vs. 72.5 years, p =.038), while patients’ sex, etiology of liver diseases, tumor size, tumor location and baseline liver function (both ALBI score and Child-Turcotte-Pugh score) were similar between the two groups. In SBRT group, median pre-ALBI and post-ALBI scores were -2.40 and -2.30, respectively, and the difference was not significant (p =.336). After propensity score matching, all the baseline characteristics were well balanced, and post-ALBI scores were not significant different between SBRT and RFA groups (-2.27 vs. -2.30, p =.828).
Conclusions
In our study, the impact of SBRT on liver function was comparable to that of RFA. Our findings help to promote SBRT as an expecting alternative treatment for early-stage HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract